TY - JOUR
T1 - Optogenetic technology
T2 - breakthroughs and challenges from basic research to clinical translation
AU - Zhao, Hongyou
AU - Yue, Hui
AU - Chou, Wenxin
AU - Yang, Shanlin
AU - Liu, Yidi
AU - He, Mianwang
AU - Li, Yunqi
AU - Guo, Jianfei
AU - Qiu, Haixia
AU - Xiao, Yilei
AU - Gu, Ying
N1 - Publisher Copyright:
© The Authors.
PY - 2025/9/1
Y1 - 2025/9/1
N2 - In the past two decades, optogenetic technology has developed to be the most accurate method for investigating or treating neural correlated diseases. Currently, the applications of optogenetic technology have been expanded from the initial central nervous system to the peripheral nervous system, circulatory system, locomotor system, alimentary system, urinary system, and so on. We summarize the recent progress of optogenetic technology in biomedical applications through two categories: activation or inhibition of neural impulses. The involved diseases include Alzheimer's disease, ischemic stroke, Parkinson's disease, epilepsy, spinal cord injury, cardiac arrhythmias, and chronic kidney disease. Furthermore, basic and clinical research in optogenetic technology for visual restoration is highlighted, and the challenges of optogenetic technology for clinical applications are discussed.
AB - In the past two decades, optogenetic technology has developed to be the most accurate method for investigating or treating neural correlated diseases. Currently, the applications of optogenetic technology have been expanded from the initial central nervous system to the peripheral nervous system, circulatory system, locomotor system, alimentary system, urinary system, and so on. We summarize the recent progress of optogenetic technology in biomedical applications through two categories: activation or inhibition of neural impulses. The involved diseases include Alzheimer's disease, ischemic stroke, Parkinson's disease, epilepsy, spinal cord injury, cardiac arrhythmias, and chronic kidney disease. Furthermore, basic and clinical research in optogenetic technology for visual restoration is highlighted, and the challenges of optogenetic technology for clinical applications are discussed.
KW - biomedical applications
KW - neuron activation
KW - neuron inhibition
KW - optogenetics
KW - photosensitive proteins
UR - https://www.scopus.com/pages/publications/105020719607
U2 - 10.1117/1.AP.7.5.054001
DO - 10.1117/1.AP.7.5.054001
M3 - Review article
AN - SCOPUS:105020719607
SN - 2577-5421
VL - 7
JO - Advanced Photonics
JF - Advanced Photonics
IS - 5
M1 - 054001
ER -